PamGene announces presentation of positive interim results for its blood-based biomarker test to predict clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC at the 2020 European Society for Medical Oncology ESMO

PamGene, a biotech and services company focused on the development and commercialization of multiple novel biomarker panels for patient stratification in immuno-oncology, is pleased to announce that new data from an ongoing multicenter prospective cohort study will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress. In this study, kinase activity profiles from peripheral blood mononuclear cells (PBMCs) are used as a biomarker to predict clinical benefit to immune Checkpoint Inhibitors (ICI) in patients with advanced stage melanoma or advanced stage non-small cell lung cancer (NSCLC).

This diagnostic test, IOpener®, is developed to guide oncologists in optimizing patient treatment and to support pharmaceutical companies to improve outcome of their clinical trials by patient stratification from a simple blood draw. This first-of-its-kind diagnostic test is based on the activity of tyrosine kinases which play a crucial role in immune checkpoint regulation and T cell response. In combination with PamGene’s proprietary software algorithms the test requires only 72 hours from sampling to providing an individual patient view of their likelihood of responding to ICI treatment.

The IOpener® is currently available as in-house developed test and is in the final phase of clinical validation for CE-IVD certification.

Title: Tyrosine kinase activity profiling as a predictive biomarker for clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC.
Poster #: 1200
Speaker: Karlijn de Joode (Rotterdam, Netherlands)

More information
Get in touch for more information.

Related Posts